“We've got geopolitical pressures, macro-economic pressures, interest rates, inflation…” Bradley Hardiman, senior director of business development at Astellas Venture Management, listed the challenges for biopharma going into 2024. “But as an industry, we've always had something that challenges us, and we've always overcome it,” he told In Vivo on the sidelines of the recent BIO-Europe conference in Munich, Germany.
Hardiman was previously an investor at Spex Capital before joining Astellas in April 2022, initially in the company’s internal business...
